I've remarked on it in the distant past. Basically, I don't think natural gene patents are going to be worth much. The BRCA patents do a fine job of muddying the water for Myriad, but the courts seem close to deciding exactly what they can be used for, after which anyone who really wants to will have a guidebook for navigating around them. A lot of them are getting old, anyway.
In principle, Incyte could collect little bits of royalties from many parties for research touching on their patented genes. That doesn't really work out because you need a way to prove infringement, and against a forewarned adversary that can be hard.